ATE549330T1 - Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens - Google Patents

Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens

Info

Publication number
ATE549330T1
ATE549330T1 AT10188688T AT10188688T ATE549330T1 AT E549330 T1 ATE549330 T1 AT E549330T1 AT 10188688 T AT10188688 T AT 10188688T AT 10188688 T AT10188688 T AT 10188688T AT E549330 T1 ATE549330 T1 AT E549330T1
Authority
AT
Austria
Prior art keywords
benzobethiophene
cns
piperazine
diseases
derivatives
Prior art date
Application number
AT10188688T
Other languages
English (en)
Inventor
Hiroshi Yamashita
Hideaki Kuroda
Nobuaki Ito
Jun Matsubara
Kunio Oshima
Kazumi Kondo
Satoshi Shimizu
Motohiro Itotani
Tae Fukushima
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of ATE549330T1 publication Critical patent/ATE549330T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT10188688T 2005-08-31 2006-08-31 Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens ATE549330T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005251055 2005-08-31

Publications (1)

Publication Number Publication Date
ATE549330T1 true ATE549330T1 (de) 2012-03-15

Family

ID=37709698

Family Applications (4)

Application Number Title Priority Date Filing Date
AT06797580T ATE499369T1 (de) 2005-08-31 2006-08-31 Heterozyklische verbindung
AT10188683T ATE557022T1 (de) 2005-08-31 2006-08-31 Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
AT10188688T ATE549330T1 (de) 2005-08-31 2006-08-31 Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
AT10188671T ATE557021T1 (de) 2005-08-31 2006-08-31 Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT06797580T ATE499369T1 (de) 2005-08-31 2006-08-31 Heterozyklische verbindung
AT10188683T ATE557022T1 (de) 2005-08-31 2006-08-31 Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT10188671T ATE557021T1 (de) 2005-08-31 2006-08-31 Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens

Country Status (25)

Country Link
US (3) US8071600B2 (de)
EP (4) EP2284169B1 (de)
JP (1) JP4785677B2 (de)
KR (2) KR20100063807A (de)
CN (4) CN102702182A (de)
AR (1) AR055203A1 (de)
AT (4) ATE499369T1 (de)
AU (2) AU2006285607B2 (de)
BR (1) BRPI0615140A2 (de)
CA (1) CA2620688C (de)
CY (1) CY1111671T1 (de)
DE (1) DE602006020294D1 (de)
DK (1) DK1919907T5 (de)
ES (4) ES2382445T3 (de)
IL (1) IL189383A (de)
MX (1) MX2008002736A (de)
MY (1) MY145670A (de)
PL (1) PL1919907T3 (de)
PT (1) PT1919907E (de)
RU (1) RU2415854C2 (de)
SG (1) SG155180A1 (de)
SI (1) SI1919907T1 (de)
TW (1) TWI329641B (de)
WO (1) WO2007026959A2 (de)
ZA (1) ZA200801888B (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1558582T3 (pl) 2003-07-22 2006-05-31 Arena Pharm Inc Diarylowe i aryloheteroarylowe pochodne mocznika jako modulatory receptora serotoninowego 5-HT2A użyteczne w profilaktyce i w leczeniu zaburzeń związanych z tym receptorem
PE20061130A1 (es) 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
CN101426774B (zh) 2006-04-19 2012-04-25 安斯泰来制药有限公司 唑类甲酰胺衍生物
KR101514846B1 (ko) 2006-05-18 2015-04-23 아레나 파마슈티칼스, 인크. ５-ｈｔ２ａ 세로토닌 수용체의 조절인자로서 유용한 페닐-피라졸의 결정질 형태 및 그의 제조 방법
AU2007254244C1 (en) 2006-05-18 2014-07-31 Arena Pharmaceuticals, Inc. 3-pyrazolyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
EP2018371B1 (de) 2006-05-18 2015-03-04 Arena Pharmaceuticals, Inc. Primäramine und derivate davon als modulatoren des 5-ht2a-serotonin-rezeptors zur behandlung damit zusammenhängender erkrankungen
TWI329102B (en) * 2006-08-15 2010-08-21 Nat Health Research Institutes Thiourea compounds and method for inhibiting hepatitis c virus infection
WO2008020306A2 (en) * 2006-08-18 2008-02-21 Pfizer Products Inc. Isoindole derivatives
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
EP1972628A1 (de) * 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizine und aza-analoge Derivate davon als CNS-aktive Verbindungen
US7985763B2 (en) * 2007-04-10 2011-07-26 National Health Research Institutes Hepatitis C virus inhibitors
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
US7897764B2 (en) * 2007-06-08 2011-03-01 National Health Research Institutes Thiourea derivatives
EA201070077A1 (ru) * 2007-06-29 2010-08-30 Эмори Юниверсити Антагонисты nmda-рецепторов с нейропротективным действием
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
WO2009025265A1 (ja) * 2007-08-21 2009-02-26 Shionogi & Co., Ltd. ピペラジン誘導体
CA2703106C (en) 2007-10-24 2015-12-01 Astellas Pharma Inc. Azolecarboxamide derivatives as trka inhibitors
JP5224616B2 (ja) * 2007-10-29 2013-07-03 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としての複素環式エーテルまたはチオエーテル誘導体
AU2009214190A1 (en) * 2008-02-15 2009-08-20 F. Hoffmann-La Roche Ag 3-alkyl-piperazine derivatives and uses thereof
PL2254873T3 (pl) 2008-02-22 2014-10-31 Otsuka Pharma Co Ltd Związek benzodiazepinowy i kompozycja farmaceutyczna
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US8198284B2 (en) * 2008-04-30 2012-06-12 National Health Research Institutes Treatment of neurodegenerative disorders with thiourea compounds
MX2010012186A (es) * 2008-05-09 2011-02-22 Univ Emory Antagonistas del receptor nmda para el tratamiento de transtornos neuropsiquitricos.
NZ590285A (en) * 2008-07-15 2012-10-26 Novartis Ag Heteroaryl derivatives as dgat1 inhibitors
KR101457339B1 (ko) * 2008-07-28 2014-11-03 지앙쑤 구오후아 인베스트먼트 컴퍼니 리미티드 아랄킬 치환된 피페리딘 또는 피페라진 유도체 및 정신분열증 치료를 위한 이의 용도
CN102131779A (zh) * 2008-09-01 2011-07-20 神经研究公司 哌啶-4-乙酰胺衍生物及其作为单胺神经递质再摄取抑制剂的应用
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
EP2364142B1 (de) 2008-10-28 2018-01-17 Arena Pharmaceuticals, Inc. Zusammensetzung eines 5-ht2a-serotonin-rezeptor-modulators zur behandlung von damit zusammenhängenden erkrankungen
PL2379525T3 (pl) * 2008-12-19 2016-01-29 Centrexion Therapeutics Corp Cykliczne pirymidyno-4-karboksamidy jako antagoniści receptora CCR2 do leczenia stanów zapalnych, astmy oraz COPD
EP3725775A1 (de) 2009-02-17 2020-10-21 Syntrix Biosystems, Inc. Pyridin- und pyrimidincarboxamide als cxcr2-modulatoren
JP5649577B2 (ja) * 2009-08-21 2015-01-07 大塚製薬株式会社 ベンゾ［ｂ］［１，４］ジアゼピン−２，４−ジオン化合物の製造方法
TWI481601B (zh) 2009-08-21 2015-04-21 Otsuka Pharma Co Ltd 含氮化合物及藥學組成物
AU2010332969B2 (en) 2009-12-17 2015-02-12 Centrexion Therapeutics Corporation New CCR2 receptor antagonists and uses thereof
WO2011075596A1 (en) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2011109679A2 (en) * 2010-03-05 2011-09-09 Amira Pharmaceuticals, Inc. Inhibitors of 5-lipoxygenase
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP5646736B2 (ja) 2010-05-12 2014-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用
EP2571870B1 (de) 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2-antagonisten und verwendungen dafür
WO2011147772A1 (en) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
WO2012027289A1 (en) 2010-08-23 2012-03-01 Syntrix Biosystems Inc. Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators
CN102206214B (zh) * 2011-04-07 2014-03-12 华中科技大学 苯并吡喃酮类衍生物及其应用
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
AR088352A1 (es) * 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
JP6345651B2 (ja) * 2012-05-09 2018-06-20 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ヘテロアリール化合物及びその使用方法
US9624197B2 (en) * 2012-11-27 2017-04-18 Merck Sharp & Dohme Corp. 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
EP2964226A4 (de) * 2013-03-08 2016-08-10 Merck Sharp & Dohme 2-pyridyloxy-4-ester-orexinrezeptorantagonisten
US10273243B2 (en) * 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
CN104059046B (zh) * 2013-03-18 2017-02-08 江苏恩华药业股份有限公司 黄酮类衍生物及其应用
CN104447723A (zh) * 2014-11-28 2015-03-25 瑞阳制药有限公司 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
HK1245660A1 (zh) 2015-06-12 2018-08-31 Axovant Sciences Gmbh 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
CA2990460C (en) 2015-07-02 2023-10-17 Centrexion Therapeutics Corporation (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
CN106749219A (zh) 2015-11-20 2017-05-31 江苏恩华药业股份有限公司 一种内酰胺类衍生物及其应用
US10464931B2 (en) 2015-12-28 2019-11-05 Honour (R&D) Process for the preparation of Quinolin-2(1H)-one derivatives
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN112079812B (zh) * 2020-09-29 2021-08-06 浙江大学 哌唑类抗精神病药物关键中间体及其电还原方法
CN112125896B (zh) * 2020-09-29 2021-10-29 湖南省湘中制药有限公司 一种抗精神病药依匹哌唑电化学制备方法
CA3199274A1 (en) 2020-10-27 2022-05-05 Arena Pharmaceuticals, Inc. Pyrimidine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
CN115772175A (zh) * 2021-09-07 2023-03-10 中国科学院分子细胞科学卓越创新中心 噻吩并环化合物及其制备方法和应用
CN116554145B (zh) * 2022-01-29 2025-06-03 江苏恩华药业股份有限公司 芳烷基-4-(1h)吲哚基哌嗪衍生物、其制备方法和应用
US12338236B2 (en) 2022-01-29 2025-06-24 Suven Life Sciences Limited Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders
CN115521298A (zh) * 2022-05-09 2022-12-27 江苏慧聚药业股份有限公司 依匹哌唑的制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0005828B1 (de) 1978-06-06 1981-03-11 Hoechst Aktiengesellschaft Neue substituierte Phenylpiperazinderivate, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung
JPS5649361A (en) 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
DK611489A (da) * 1988-12-08 1990-06-09 Duphar Int Res Anxiolytisk aktive piperazinderivater og farmaceutiske praeparater med indhold af saadanne forbindelser
FI920023A7 (fi) 1989-07-07 1992-01-03 Pfizer Heteroaryylipiperatsiiniyhdisteet antipsykootteina
CA2067475C (en) 1991-05-08 2000-10-10 Yasuo Oshiro Carbostyril derivatives and their use
US5240927A (en) * 1992-05-19 1993-08-31 Hoechst-Roussel Pharmaceuticals Incorporated Benzo[β]thiophen-3-yl piperazines as antipsychotic agents
DK148292D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
EP0732332B1 (de) 1995-03-17 2001-12-19 Aventis Pharmaceuticals Inc. Substituierte Benzylthienylpiperazine, ihre Anwendung als Arzneimittel und Verfahren für ihre Herstellung
FR2740134B1 (fr) 1995-10-18 1998-01-09 Pf Medicament Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant
EP0934932A4 (de) 1996-08-22 2002-06-26 Meiji Seika Kaisha Chinolinderivate und psychotropes mittel
FR2761068B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de piperazin-4-ylthieno[3,2-c]pyridin-4-yl-2- carboxamide, leur preparation et leur application en therapeutique
EP1188747B1 (de) 1999-05-24 2005-09-07 Mitsubishi Pharma Corporation Phenoxypropylamin-derivate
AR027133A1 (es) * 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
AR027134A1 (es) * 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de indol.
IL157412A0 (en) 2001-02-16 2004-03-28 Aventis Pharmaceuticals Inc Av Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
US6982332B2 (en) 2001-06-07 2006-01-03 Wayne State University Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering CNS activity
ATE304007T1 (de) * 2001-06-29 2005-09-15 Lundbeck & Co As H Neue indolderivate
AP2005003250A0 (en) 2002-09-17 2005-03-31 Warner Lambert Co Heterocyclic substituted piperazines for the treatment of schizophrenia.
WO2004029048A1 (en) 2002-09-26 2004-04-08 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物

Also Published As

Publication number Publication date
PL1919907T3 (pl) 2011-07-29
EP2284169A1 (de) 2011-02-16
ES2362961T3 (es) 2011-07-15
US8598162B2 (en) 2013-12-03
AU2010200362A1 (en) 2010-02-18
DE602006020294D1 (de) 2011-04-07
CN102702182A (zh) 2012-10-03
MX2008002736A (es) 2008-03-26
ZA200801888B (en) 2009-07-29
US20140031334A1 (en) 2014-01-30
AU2006285607B2 (en) 2010-02-25
US20090264404A1 (en) 2009-10-22
US8071600B2 (en) 2011-12-06
HK1119707A1 (zh) 2009-03-13
ES2383948T3 (es) 2012-06-27
ATE557022T1 (de) 2012-05-15
KR20100063807A (ko) 2010-06-11
DK1919907T3 (da) 2011-04-18
RU2008112224A (ru) 2009-10-10
ES2382445T3 (es) 2012-06-08
TWI329641B (en) 2010-09-01
EP1919907A2 (de) 2008-05-14
WO2007026959A3 (en) 2007-08-16
ATE557021T1 (de) 2012-05-15
CN101258147B (zh) 2012-03-21
IL189383A0 (en) 2008-06-05
EP2287162A1 (de) 2011-02-23
EP2287161B1 (de) 2012-05-09
ES2362961T9 (es) 2012-02-13
AR055203A1 (es) 2007-08-08
AU2006285607A1 (en) 2007-03-08
IL189383A (en) 2013-03-24
CA2620688C (en) 2014-03-25
EP2287161A1 (de) 2011-02-23
EP1919907B1 (de) 2011-02-23
SG155180A1 (en) 2009-09-30
CN102558140A (zh) 2012-07-11
EP1919907B9 (de) 2012-01-18
TW200800937A (en) 2008-01-01
ATE499369T1 (de) 2011-03-15
BRPI0615140A2 (pt) 2010-01-12
RU2415854C2 (ru) 2011-04-10
MY145670A (en) 2012-03-15
DK1919907T5 (da) 2011-09-12
JP4785677B2 (ja) 2011-10-05
KR20080033446A (ko) 2008-04-16
SI1919907T1 (sl) 2011-05-31
WO2007026959A2 (en) 2007-03-08
CA2620688A1 (en) 2007-03-08
EP2284169B1 (de) 2012-03-14
CY1111671T1 (el) 2015-10-07
CN102850336A (zh) 2013-01-02
JP2007091733A (ja) 2007-04-12
CN101258147A (zh) 2008-09-03
PT1919907E (pt) 2011-03-23
KR101008873B1 (ko) 2011-01-19
US20120028920A1 (en) 2012-02-02
EP2287162B1 (de) 2012-05-09
ES2383949T3 (es) 2012-06-27

Similar Documents

Publication Publication Date Title
ATE557022T1 (de) Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
ATE399155T1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
DE602007004092D1 (de) C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE537150T1 (de) Zur behandlung gynäkologischer erkrankungen geeignete pyrazolderivate
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
EP3769718C0 (de) Vorrichtung zur behandlung von darmerkrankungen
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
ATE439843T1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
ATE448228T1 (de) Pyrrolopyrimidinderivate zur behandlung proliferativer krankheiten